Core Scientific, Inc. CORZ
17.34
(0.79)
(4.36%)
as of 25 Sep
- Market cap
- $5.9B
- P/E
- 0.0×
Follow CORZ
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
17.10 | 14.52 | 13.62 | 18.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
41.95 | 30.26 | 19.33 | (439.83) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
18.91 | 16.86 | 13.61 | 24.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
45.48 | 19.34 | 8.42 | 20.54 | |
EV/FCF |
(17.94) | (11.76) | (10.37) | (8.95) | |
Quick Ratio |
0.68 | 0.40 | 0.40 | 0.71 | |
Current Ratio |
1.58 | 1.15 | 0.55 | 0.89 | |
Net Debt/EBITDA |
(18.04) | (7.77) | 0.01 | (38.47) | |
Debt/Assets |
46.12% | 45.17% | 34.59% | 81.75% | |
Debt/Equity |
(0.94) | (1.10) | (0.81) | (1.78) | |
Asset Turnover |
0.21 | 0.17 | 0.15 | 0.12 | |
Operating CF/Net income |
(0.92) | (0.27) | (0.73) | 0.02 | |
Capex/Depreciation |
(10.85) | (14.83) | (17.99) | (46.68) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
85.51% | 0.00% | 38.91% | 30.08% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.04 | |
Share Based Compensation of Revenue |
36.92% | 35.02% | 15.41% | 11.11% | |
Graham Net Nets |
(0.41) | (0.52) | (0.60) | (0.63) | |
Graham Number |
14.30 | 9.65 | 18.75 | 26.64 | |
Earnings Yield |
(14.30%) | (9.38%) | (25.84%) | (16.57%) | |
Free Cash Flow Yield |
(6.16%) | (9.88%) | (9.63%) | (14.35%) | |
Revenue per Share |
0.25 | 0.25 | 0.36 | 0.50 | |
Operating CF per Share |
0.43 | 0.48 | 0.77 | (0.06) | |
Capex per Share |
(0.81) | (0.86) | (1.20) | (2.45) | |
Free Cash Flow per Share |
(0.38) | (0.38) | (0.42) | (2.51) | |
Cash per Share |
1.42 | 0.98 | 3.30 | 5.95 | |
Shareholders Equity per Share |
(3.54) | (3.03) | (4.04) | (7.44) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.54) | (3.03) | (4.04) | (7.44) | |
Free Cash Flow |
(122.61) | (120.26) | (136.77) | (815.09) | |
Working Capital |
391.17 | 114.14 | (1,206.95) | (294.15) | |
Capital Expenditures |
(258.84) | (273.32) | (386.65) | (796.16) | |
Net Current Asset Value |
(2,362.91) | (2,414.85) | (2,920.42) | (5,233.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.19 | 3.43 | 3.36 | 4.85 | |
Net Profit Margin |
(181.88%) | (723.03%) | (297.14%) | (658.39%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
109.34 | 72.69 | 112.59 | 163.71 | |
Average Assets |
1,608.92 | 1,911.80 | 2,347.47 | 3,617.77 | |
Average Common Equity |
(928.68) | (952.89) | (743.60) | (1,742.02) |
Columns are period end dates